Navigation Links
EDARBYCLOR (azilsartan medoxomil and chlorthalidone) Now Available in U.S. Pharmacies for Patients with Hypertension
Date:2/6/2012

hypertension patients are not at their blood pressure targets, putting them at increased cardiovascular risk," said Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. "We're pleased to bring EDARBYCLOR to market and expand the EDARBI family of products to help appropriate patients with hypertension work towards reaching their blood pressure goals."

About Hypertension
Hypertension, or high blood pressure, is a chronic medical condition in which blood pressure is elevated to levels of 140 mm Hg or greater systolic and/or 90 mm Hg or greater diastolic. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Control of high blood pressure should be part of comprehensive cardiovascular risk management including, as appropriate, lipid control, management of diabetes, prevention of blood clots, smoking cessation, exercise and limited sodium intake.

Hypertension impacts approximately 76 million Americans, or nearly one in three adults. It is estimated that nearly one billion people are affected by hypertension worldwide, and this figure is predicted to increase to 1.5 billion by 2025. Hypertension typically has no symptoms. Adults of all ages and backgrounds can develop hypertension; however, the risk of developing the condition increases with age, with more than half of people over age 60 affected. Hypertension is also costly to the nation's health care system. The American Heart Association recently estimated that direct and indirect expenses associated with hypertension cost the nation more than $73 billion in 2009.

About EDARBI and EDARBYCLOR
EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) developed by Takeda for the treatment of hypertension to lower blood pressure in adults. EDARBI lowers blood pressure b
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension
2. EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients With Hypertension
3. FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension
4. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
5. New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
6. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
7. NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription
8. PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States
9. Nearly 9 Million Kaiser Permanente Health Records Securely Available on Mobile Devices
10. Edgemont - New Fluoxetine Tablets, 60 mg Now Available
11. Simbionix Comprehensive Medical Simulators now Available in Additional Languages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... analog IC solutions, today announced that it will host ... at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) ... 2014 third quarter ended June 30, 2014. ... before 6:50 a.m. Pacific time on July 24, 2014.  ...
(Date:7/10/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... completed the sale to Galderma of all rights to ... by Valeant for $1.4 billion in cash, pursuant to ... completed its acquisition of Galderma. "We ... to a company that is firmly committed to the ...
(Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
Breaking Medicine Technology:
... DIEGO, May 4, 2011 Volcano Corporation (NASDAQ: ... precision intravascular diagnosis and therapy guidance tools designed to ... said today that it will be participating in the ... Wednesday, May 11. The presentation by Scott ...
... Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX ), ... commercialization of medically important pharmaceutical products for the treatment ... today announced the pricing of an underwritten registered offering ... price of $4.70 per share. The aggregate ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering 2
(Date:7/10/2014)... 10, 2014 Register to download the ... streamed the live webinar ‘Capitalizing on the Shifting Sands ... group of several M&A experts in the energy sector ... energy transaction marketplace. These experts shared their insights into ... market in this sector has been revitalized. This roundtable ...
(Date:7/10/2014)... MI (PRWEB) July 10, 2014 ... treatment program that gets clients off to a great ... they can believe in, has launched a new Eating ... , The new section highlights:, , ... and Statistic Manual of Mental Disorders (DSM-IV), including anorexia ...
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Nature, not ... intelligence of individual chimpanzees, a new study finds. ... it comes to cognitive [thinking] abilities in chimpanzees," William ... Atlanta, said in a news release from the journal ... give insight into the evolution of intelligence in humans, ...
(Date:7/10/2014)... News) -- Men who have a vasectomy may be ... study suggests. But the risk is comparatively small, ... the study said more research is needed to determine ... the study, Harvard researchers analyzed data from more than ... starting in 1986. During that time, 6,023 cases of ...
(Date:7/10/2014)... experts on aggression, who research issues ranging from child ... World Meeting of the International Society for Research on ... , Georgia State University is hosting the prestigious world ... continents. , "We are excited to be bringing together ... will help produce fresh ideas about the causes, consequences ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3
... Study reports high success rate for new test, with results ... A new test can rapidly identify active tuberculosis in people ... about half of all people with active TB, the disease-causing ... new diagnostic tests are needed to help control the spread ...
... Irvine researchers have created a new approach that ... specific cells and organs. Kenneth Longmuir, associate ... professor of anatomy & neurobiology, used liposomes, small ... lipid molecules, as "packages" for the cancer chemotherapeutic ...
... N.Y., SEPT. 25, 2009 Journalists are invited to attend ... health care experts who will review and develop programs that ... The symposium, which will be held Oct. 8 and ... March of Dimes, the American College of Obstetricians and Gynecologists, ...
... testing effects on women and their offspring, , FRIDAY, ... women can cause serious consequences in both mothers and ... treatments. , An update on clinical trials was to ... American Thyroid Association, in Palm Beach, Fla. , "Detection ...
... ... costs, saving time and money , ... Philadelphia, PA (PRWEB) September 25, 2009 -- Observations from Excel ... Philadelphia region, indicate that awareness levels for Direct Access, a law that allows people ...
... causes gastric cancer, it is still controversial that whether ... prevention of gastric cancer. This is especially important for Yamagata ... of gastric cancer in the world. A research ... World Journal of Gastroenterology addresses this question. A ...
Cached Medicine News:Health News:Faster Detection of TB May Be on the Horizon 2Health News:UCI researchers create new strategy for highly selective chemotherapy delivery 2Health News:Experts to review quality improvement programs to prevent preterm birth 2Health News:Experts to review quality improvement programs to prevent preterm birth 3Health News:Studies Evaluate Thyroid Treatment During Pregnancy 2Health News:According to Excel Physical Therapy and Fitness, Awareness Still Low for Law that Allows People to go Directly to a Physical Therapist without a Doctor's Prescription 2Health News:According to Excel Physical Therapy and Fitness, Awareness Still Low for Law that Allows People to go Directly to a Physical Therapist without a Doctor's Prescription 3Health News:Does Helicobacter pylori eradication therapy prevent gastric cancer? 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... (RAM) is the first visual examination device that ... in eyes with glaucoma, cataract, and macular disease. ... test each eye easily in under 60 seconds. ... Columbia University in New York City, the RAM ...
... The STRATUSOCT is a diagnostic imaging device ... the retina for objective measurement and subjective ... and retinal diseases. The STRATUSOCT images and ... layer and the optic disc using the ...
The Hybrid Fixator consists of Three basic components: rings, wires, clamps. Final fracture reduction can be easily performed after frame assembly....
Medicine Products: